| Authors: |
Pflug A; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Schimpl M; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Nissink JWM; Oncology R&D, AstraZeneca, Cambridge, U.K., Overman RC; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Rawlins PB; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Truman C; Mechanistic Biology and Profiling, Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Underwood E; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Warwicker J; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Winter-Holt J; Oncology R&D, AstraZeneca, Cambridge, U.K., McCoull W; Oncology R&D, AstraZeneca, Cambridge, U.K. |